Pharmacy, 2021 The use of long-acting lipoglycopeptides (LaLGPs) in serious, deep-seated infections is of increasing interest. The purpose of this study is to evaluate the economic and clinical utility of LaLGPs in patients requiring protracted antibiotic courses who ...
Kayla Antosz +7 more
doaj +3 more sources
New Frontier on Antimicrobial Therapy: Long-Acting Lipoglycopeptides
PathogensLong-acting lipoglycopeptides (LGPs), such as dalbavancin and oritavancin, are semisynthetic antibiotics known for their strong effectiveness against a wide array of Gram-positive bacteria. This includes Staphylococcus aureus, both methicillin-sensitive (
Valentina Siciliano +6 more
exaly +3 more sources
Comparative Activity of Lipoglycopeptide Antibiotics Against Gram-Positive Bacteria
Антибиотики и Химиотерапия, 2022 Lipoglycopeptide antibiotics are semi-synthetic derivatives of glycopeptides and are characterized by a pronounced bactericidal activity against gram-positive pathogens.
V. V. Gostev +12 more
doaj +1 more source
Microbiology Spectrum, 2023 Dalbavancin is a second-generation lipoglycopeptide antibiotic with activity against Gram-positive organisms. Dalbavancin is Food and Drug Administration (FDA)-approved for acute bacterial skin and soft tissue infections (ABSSTIs).
Richard Lueking +4 more
doaj +1 more source
Frontiers in Microbiology, 2022 Gausemycin A is the first member of the novel lipoglycopeptides family produced by Streptomyces roseoflavus INA-Ac-5812. Gausemycin A has a pronounced bactericidal activity against methicillin-resistant Staphylococcus aureus.
Darya V. Poshvina +7 more
doaj +1 more source
New Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians
Pharmaceuticals, 2023 Antibiotic resistance is a public health problem with increasingly alarming data being reported. Gram-positive bacteria are among the protagonists of severe nosocomial and community infections.
Davide Carcione +13 more
doaj +1 more source
New Antibiotics for Staphylococcus aureus Infection: An Update from the World Association of Infectious Diseases and Immunological Disorders (WAidid) and the Italian Society of Anti-Infective Therapy (SITA) [PDF]
, 2023 Staphylococcus aureus is an extremely virulent pathogen that is capable of quickly evolving and developing antibiotic resistance. To overcome this problem, new antibiotics have been developed.
Bassetti M. +11 more
core +4 more sources
In vitro synergy of 5-nitrofurans, vancomycin and sodium deoxycholate against Gram-negative pathogens [PDF]
, 2021 Introduction. There is an urgent need for effective therapies against bacterial infections, especially those caused by antibiotic-resistant Gram-negative pathogens. Hypothesis.
Davenport C +3 more
core +2 more sources
Patients with serious injection drug use-related infections who experience patient-directed discharges on oral antibiotics have high rates of antibiotic adherence but require multidisciplinary outpatient support for retention in care [PDF]
, 2022 Background: Persons who inject drugs (PWID) are frequently admitted for serious injection-related infections (SIRIs). Outcomes and adherence to oral antibiotics for PWID with patient-directed discharge (PDD) remain understudied.
Durkin, Michael J +7 more
core +2 more sources
A Narrative Review of Staphylococcus hominis Resistance Pattern: Multidrug- and Possible Extensively Drug-Resistance [PDF]
, 2023 Staphylococcus hominis is the third most frequent opportunistic pathogen in neonates and immunosuppressed patients that cause bacteremia, septicemia, endophthalmitis, and endocarditis. The emergence of methicillin resistant Staphylococcus hominis (MRSHo)
Juanita, Rr. Asih +3 more
core +2 more sources